Literature DB >> 20053336

CCR5 expression on cells from HLA-matched unrelated marrow donors and graft-versus-host disease.

Qing Ma, Ted A Gooley, Rainer F Storb.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 20053336      PMCID： PMC2804929          DOI： 10.1016/j.bbmt.2009.05.017

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN： 1083-8791            Impact factor:   5.742


× No keyword cloud information.
  10 in total

1.  Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study.

Authors:  M W Smith; M Dean; M Carrington; C Winkler; G A Huttley; D A Lomb; J J Goedert; T R O'Brien; L P Jacobson; R Kaslow; S Buchbinder; E Vittinghoff; D Vlahov; K Hoots; M W Hilgartner; S J O'Brien
Journal:  Science       Date:  1997-08-15       Impact factor: 47.728

Review 2.  The chemokine system and CCR5 antagonists: potential in HIV treatment and other novel therapies.

Authors:  H Dhami; C E Fritz; B Gankin; S H Pak; W Yi; M-J Seya; R B Raffa; S Nagar
Journal:  J Clin Pharm Ther       Date:  2009-04       Impact factor: 2.512

3.  CCR5-delta 32 gene deletion in HIV-1 infected patients.

Authors:  M W Smith; M Dean; M Carrington; G A Huttley; S J O'Brien
Journal:  Lancet       Date:  1997-09-06       Impact factor: 79.321

4.  Active participation of CCR5(+)CD8(+) T lymphocytes in the pathogenesis of liver injury in graft-versus-host disease.

Authors:  M Murai; H Yoneyama; A Harada; Z Yi; C Vestergaard; B Guo; K Suzuki; H Asakura; K Matsushima
Journal:  J Clin Invest       Date:  1999-07       Impact factor: 14.808

5.  CC chemokine receptor 5 and renal-transplant survival.

Authors:  M Fischereder; B Luckow; B Hocher; R P Wüthrich; U Rothenpieler; H Schneeberger; U Panzer; R A Stahl; I A Hauser; K Budde; H Neumayer; B K Krämer; W Land; D Schlöndorff
Journal:  Lancet       Date:  2001-06-02       Impact factor: 79.321

6.  T-lymphocyte production of macrophage inflammatory protein-1alpha is critical to the recruitment of CD8(+) T cells to the liver, lung, and spleen during graft-versus-host disease.

Authors:  J S Serody; S E Burkett; A Panoskaltsis-Mortari; J Ng-Cashin; E McMahon; G K Matsushima; S A Lira; D N Cook; B R Blazar
Journal:  Blood       Date:  2000-11-01       Impact factor: 22.113

Review 7.  Chemokines as regulators of T cell differentiation.

Authors:  S A Luther; J G Cyster
Journal:  Nat Immunol       Date:  2001-02       Impact factor: 25.606

8.  Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia.

Authors:  J A Hansen; T A Gooley; P J Martin; F Appelbaum; T R Chauncey; R A Clift; E W Petersdorf; J Radich; J E Sanders; R F Storb; K M Sullivan; C Anasetti
Journal:  N Engl J Med       Date:  1998-04-02       Impact factor: 91.245

Review 9.  Chemokine receptor-dependent alloresponses.

Authors:  Wayne W Hancock
Journal:  Immunol Rev       Date:  2003-12       Impact factor: 12.988

10.  Peyer's patch is the essential site in initiating murine acute and lethal graft-versus-host reaction.

Authors:  Masako Murai; Hiroyuki Yoneyama; Taichi Ezaki; Makoto Suematsu; Yuya Terashima; Akihisa Harada; Hiromasa Hamada; Hitoshi Asakura; Hiromichi Ishikawa; Kouji Matsushima
Journal:  Nat Immunol       Date:  2003-01-13       Impact factor: 25.606
  10 in total
  8 in total

1.  Chemokine receptor CCR5 mediates alloimmune responses in graft-versus-host disease.

Authors:  Lisa A Palmer; George E Sale; John I Balogun; Dan Li; Dan Jones; Jeffrey J Molldrem; Rainer F Storb; Qing Ma
Journal:  Biol Blood Marrow Transplant       Date:  2009-12-16       Impact factor: 5.742

2.  Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease.

Authors:  Ran Reshef; Selina M Luger; Elizabeth O Hexner; Alison W Loren; Noelle V Frey; Sunita D Nasta; Steven C Goldstein; Edward A Stadtmauer; Jacqueline Smith; Sarah Bailey; Rosemarie Mick; Daniel F Heitjan; Stephen G Emerson; James A Hoxie; Robert H Vonderheide; David L Porter
Journal:  N Engl J Med       Date:  2012-07-12       Impact factor: 91.245

3.  Clinical and immunologic impact of CCR5 blockade in graft-versus-host disease prophylaxis.

Authors:  Ryan H Moy; Austin P Huffman; Lee P Richman; Lisa Crisalli; Ximi K Wang; James A Hoxie; Rosemarie Mick; Stephen G Emerson; Yi Zhang; Robert H Vonderheide; David L Porter; Ran Reshef
Journal:  Blood       Date:  2017-01-05       Impact factor: 22.113

4.  Pharmacodynamic Monitoring Predicts Outcomes of CCR5 Blockade as Graft-versus-Host Disease Prophylaxis.

Authors:  Austin P Huffman; Lee P Richman; Lisa Crisalli; Alex Ganetsky; David L Porter; Robert H Vonderheide; Ran Reshef
Journal:  Biol Blood Marrow Transplant       Date:  2017-10-20       Impact factor: 5.742

5.  The effect of the CCR5-delta32 deletion on global gene expression considering immune response and inflammation.

Authors:  Gero Hütter; Martin Neumann; Daniel Nowak; Stefan Klein; Harald Klüter; Wolf-K Hofmann
Journal:  J Inflamm (Lond)       Date:  2011-10-26       Impact factor: 4.981

Review 6.  Achievement of Tolerance Induction to Prevent Acute Graft-vs.-Host Disease.

Authors:  Govindarajan Thangavelu; Bruce R Blazar
Journal:  Front Immunol       Date:  2019-03-06       Impact factor: 7.561

7.  The Biological and Clinical Relevance of G Protein-Coupled Receptors to the Outcomes of Hematopoietic Stem Cell Transplantation: A Systematized Review.

Authors:  Hadrien Golay; Simona Jurkovic Mlakar; Vid Mlakar; Tiago Nava; Marc Ansari
Journal:  Int J Mol Sci       Date:  2019-08-09       Impact factor: 5.923

8.  γδ T Cells May Aggravate Acute Graft-Versus-Host Disease Through CXCR4 Signaling After Allogeneic Hematopoietic Transplantation.

Authors:  Ning Wu; Ruoyang Liu; Shuang Liang; Haitao Gao; Lan-Ping Xu; Xiao-Hui Zhang; Jiangying Liu; Xiao-Jun Huang
Journal:  Front Immunol       Date:  2021-07-14       Impact factor: 7.561
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.